By Stephen Nakrosis
Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years.
The company said it is planning to increase its R&D activity with a new $1.1 billion research hub in the San Diego area, its second in the U.S. The new complex is expected to open between 2028 and 2029.
Novartis also intends to build four new manufacturing facilities, including 3 which will make biologics drug substances, drug products, device assembly and packaging. The other facility will make chemical drug substances, oral solids dosage forms and packaging. The new manufacturing capacity will enable Novartis to produce 100% of its key medicines end-to-end in the U.S., according to the company.
The company also plans to construct a pair of radioligand therapy manufacturing facilities in Florida and Texas, and expand three RLT manufacturing facilities in Indianapolis, Millburn, NJ, and Carlsbad, CA.
The investments will give Novartis manufacturing capacity in the U.S. for all its core technology platforms, including small molecules and biologics, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 10, 2025 14:29 ET (18:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。